CIP
SMMT icon

Cornerstone Investment Partners’s Summit Therapeutics SMMT Stock Holding History

Cornerstone Investment Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-34,825
Closed -$103K – 190
2020
Q2 		$103K Buy
+34,825
New +$120K 0.01% 162

Other funds holding SMMT

PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BP
BBR Partners New York $1.79B AUM 16.83% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Cornerstone Investment Partners's SMMT Position: Q3 2020 in Review

Cornerstone Investment Partners sold out of Summit Therapeutics (SMMT) in Q3 2020, closing a stake of 34,825 shares — an estimated $103K sold.

Cornerstone Investment Partners first reported a position in SMMT in Q2 2020 and held it in 1 quarter. The position peaked at $103K in Q2 2020. 19 funds tracked by Wall St. Rank hold SMMT as of Q3 2020.

  • Cornerstone Investment Partners reported no remaining Summit Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Cornerstone Investment Partners sold 34,825 Summit Therapeutics shares in Q3 2020, an estimated $103K.
  • Cornerstone Investment Partners first reported a position in Summit Therapeutics in Q2 2020 and held it in 1 quarter.
  • Cornerstone Investment Partners's Summit Therapeutics position peaked at $103K in Q2 2020.
  • 19 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2020.

Based on Cornerstone Investment Partners's 13F filing for Q3 2020, filed 30 Oct 2020.